By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Senolytics for fatty liver: a first glimmer of hope for advanced disease
Senolytics are drugs that clear old, damaged cells from the body. Now, for the first time, a controlled human trial has tested senolytics in advanced fatty liver disease. The researchers published the study in Nature Metabolism in October 2026. The result is striking: in almost half of the patients, liver scarring regressed within 21 weeks. However, this was a very small trial. So it is important to understand what it shows, and what it does not.
In this article, I will walk you step by step through the terms, the trial design and the results. I will also cover other approaches and compounds that scientists are exploring today.
What is fatty liver, and when does it become dangerous?
Fatty liver is a condition in which fat builds up inside liver cells. Its full medical name is MASLD, which stands for metabolic dysfunction-associated steatotic liver disease. The disease goes hand in hand with obesity, type 2 diabetes and high blood lipids. According to recent estimates, its worldwide prevalence is approaching 40%.
In most people, the fat alone does not cause immediate harm. In some, though, inflammation develops as well, and it damages liver cells. Doctors call this stage MASH, or metabolic dysfunction-associated steatohepatitis. For example, people living with obesity and type 2 diabetes are at high risk of reaching it.
Long-standing inflammation leads to the next stage: fibrosis, or scarring. Stiff scar tissue gradually replaces healthy liver tissue. Doctors grade the scarring from F0, a liver with no scars, up to F4. Stage F4 is cirrhosis, in which the whole liver is scarred and struggles to function. That is why the fibrosis stage is the single most important predictor of complications and death. I cover this in more depth in my complete guide to fatty liver.
Senescent cells: the body’s “zombie cells”
To understand the new treatment, you need to know one concept: senescence, or cellular aging. When a cell is damaged, for instance in its DNA, it stops dividing. This is a clever defense mechanism that keeps a damaged cell from turning into a tumor. In the short term, it also helps wounds heal.
The trouble starts when these cells pile up. First, they refuse to die. They resist apoptosis, the orderly self-destruct process the body uses to clear out faulty cells. Second, they constantly release a mix of substances that promote inflammation and scarring. Scientists call this mix SASP, the senescence-associated secretory phenotype. This is why these cells earned the nickname “zombie cells“: they are neither truly alive nor dead, and they harm their neighbors.
The buildup of senescent cells is one of the hallmarks of aging. Earlier studies also linked it to liver inflammation and scarring. In a liver with MASH, both the liver cells themselves and the “star cells” can become senescent. These star cells, called hepatic stellate cells, are the ones that produce scar tissue. Hence the question: what would happen if we cleared these cells out?
What are senolytics, and how do they work?
The word “senolytics” has two parts: “seno,” meaning old age, and “lysis,” meaning breakdown. Senolytic drugs selectively kill senescent cells while sparing healthy ones. How is that possible? Senescent cells survive thanks to special “survival networks” that shield them from death. These drugs disable those networks. As a result, the senescent cell loses its shield and dies, whereas a healthy cell does not depend on that shield.
The oldest and most studied combination is known as D+Q, and it includes two compounds:
Dasatinib is a prescription drug from the tyrosine kinase inhibitor family. Europe has approved it, and doctors use it to treat certain types of leukemia.
Quercetin is a flavonoid, a natural plant compound. It occurs in onions and apples, for example, and stores also sell it as a dietary supplement.
Each of the two targets a different survival network, so they complement each other. Researchers at the Mayo Clinic and their colleagues identified this combination back in 2015.
Moreover, this treatment has a unique feature: it is given intermittently, in a “hit and run” approach. Senescent cells do not divide, and they take weeks to build up again. So there is no need for a daily pill; a few treatment days every so often are enough. Indeed, in an early trial in patients with diabetic kidney disease, just three days of treatment lowered markers of senescent cells.
How the trial tested senolytics in fatty liver
The trial took place at Amsterdam University Medical Center between July 2023 and February 2026. The researchers described it as a phase 2 “proof-of-principle” trial. In other words, it was an early trial designed to find out whether the idea works at all. Here are its three design principles:
Randomized: a random draw decided who would receive the treatment and who would not.
Placebo-controlled: the control group received a placebo, pills that looked identical but had no active ingredient.
Double-blind: neither the patients nor the doctors knew who was getting what.
The trial enrolled 31 patients with MASH and stage F2 to F3 fibrosis. Their median age was 56, and 58% of them had type 2 diabetes. Of these, 17 received D+Q and 14 received a placebo.
The dose was 100 mg of dasatinib and 1,000 mg of quercetin a day. Patients took the pills on three consecutive days a week for three weeks. A four-week break followed. This seven-week cycle ran three times. In total, the trial lasted 21 weeks, with only 27 treatment days.
Every participant had a liver biopsy at the start and at the end of the trial. A biopsy is a tiny tissue sample, taken with a needle and examined under a microscope. Three pathologists graded the samples without knowing who had been treated. The main goal, set in advance, was an improvement of at least one fibrosis stage with no worsening of inflammation. You can find the trial details in the ClinicalTrials.gov registry.
The results: senolytics reversed fatty liver scarring in almost half the patients
Improvement in liver scarring
In the treatment group, 8 of 17 patients met the goal, or 47%. By contrast, only 1 of 14 patients in the placebo group met it, or 7%. The P value was 0.02. Put simply, if the treatment did not work at all, a gap this large would appear by chance in only about 2 out of 100 trials.
Improvement in inflammation
The inflammation also calmed down. In 9 of the 17 D+Q patients, or 53%, the steatohepatitis resolved. In the placebo group, this happened in 1 of 14 patients, or 7%. The disease activity score, NAS, also fell by an average of 1.43 points in the treatment group. In the placebo group, it fell by only 0.39 points. This score, the NAFLD Activity Score, ranges from 0 to 8 and sums up fat, inflammation and cell damage.
What did senolytics reveal inside fatty liver cells?
The researchers did not stop at the microscope. They also analyzed the samples with an advanced method called snRNA-seq, or single-nucleus RNA sequencing. This method shows which genes are active in each individual cell. That way, they could check whether the treatment actually did what it was expected to do.
And indeed, in the treatment group, the activity of genes typical of senescent cells went down. At the same time, the activity of genes that build scar tissue also fell, including the genes for collagen production. What’s more, the share of stellate cells and inflammatory cells in the liver dropped, while the share of liver cells rose. In the placebo group, on the other hand, the trend went the other way. These findings strengthen confidence in the result, because they fit the proposed mechanism.
What did not improve?
It is just as important to say what did not change. Liver enzymes in the blood dropped slightly, but the difference versus placebo was not significant. The same was true for insulin levels, insulin resistance and blood sugar. Likewise, the noninvasive fibrosis measures showed no difference between the groups. These measures include blood tests as well as a liver stiffness scan. According to the researchers, the trial may have been too small to detect such changes.
Safety: side effects of senolytics in fatty liver
Side effects were much more common in the treatment group. In that group, 14 of 17 patients, or 82%, reported at least one side effect. In the placebo group, 6 of 14, or 43%, reported one. Most side effects were mild to moderate and went away on their own. The most common was headache, followed by digestive complaints. One patient left the trial because of digestive complaints and fatigue.
On the plus side, the researchers saw no bone marrow suppression. Nor did they see QT prolongation on the heart tracing (ECG). These were two side effects they had worried about in advance. Still, platelet counts were lower in the treatment group at the end of the trial. Platelets are the blood components responsible for clotting, so this finding calls for monitoring in future trials.
During the trial, doctors diagnosed one participant with esophageal cancer. According to the researchers, his medical workup had begun before the trial, and he had not reported it. The researchers also examined genetic pathways linked to liver cancer and found no change in them. This is an important point, because cellular senescence is also a mechanism that protects against tumors.
Limitations: is it too early to celebrate senolytics for fatty liver?
The researchers themselves are cautious, and rightly so. First, the trial is very small. The main result rests on only nine patients who improved, in both groups combined. As a result, the range of uncertainty is very wide. The treatment raised the odds of improvement 6.59-fold, but the plausible range ran from 0.93 to 46.53. In other words, the data cannot fully rule out zero effect.
Second, four participants did not complete the trial. When the researchers assumed the worst-case scenario for them, the result was no longer significant. Third, the groups were not identical at the outset. In the treatment group, 76.5% had diabetes, compared with 35.7% in the placebo group.
Finally, the trial ran at a single center and lasted only 21 weeks. We do not know whether the improvement lasts over time, or what the long-term safety looks like. That is why the researchers call the finding “hypothesis-generating,” not definitive proof. They are calling for a large trial to confirm it.
Other senolytics and compounds under study
D+Q is not the only candidate. A review of the path from the lab to the clinic describes a range of compounds at various stages of research. Here are the most prominent ones.
Fisetin: a flavonoid from nature
Fisetin is a “relative” of quercetin, found in strawberries, for example. In a mouse study, it was the most potent of ten flavonoids tested, and it even extended the mice’s lifespan. In humans, however, there is still no proof that it works. Clinical trials on it are underway.
Navitoclax and BCL-2 inhibitors
Scientists originally developed navitoclax to treat cancer. It blocks proteins of the BCL-2 family, which protect senescent cells from death. But those same proteins are also essential for platelets. As a result, the drug lowers the platelet count, which limits its use.
Next-generation senolytics
Biotech companies are now developing more targeted molecules. One example is RLS-1496, which acts on an enzyme called GPX4. In March 2026, the developer announced positive preliminary results from a phase 1 trial. The trial tested a topical ointment in patients with psoriasis and atopic dermatitis. Note that this is a company announcement, not a peer-reviewed paper.
CAR-T cells against senescent cells
Another direction comes from immunotherapy. CAR-T cells are immune cells genetically engineered to recognize a specific target. Researchers programmed such cells to attack senescent cells. In mice with liver scarring, the treatment restored the tissue. So far, this is animal research only.
Senomorphics: silencing instead of clearing
Not every approach tries to kill these cells. Senomorphics are a group of compounds that aim to silence their harmful secretions. In this context, researchers are testing older drugs such as metformin and rapamycin. I wrote about them in my article on longevity drugs.
Not every trial succeeded
It is worth remembering that the human picture is mixed. For example, in a trial in postmenopausal women, D+Q did not improve the bone breakdown marker, which was the primary goal. Meanwhile, a small trial in pulmonary fibrosis and a feasibility trial in mild Alzheimer’s disease mainly assessed feasibility and safety. The liver trial went a step further: it examined the tissue itself by biopsy and found improvement.
Fatty liver treatments beyond senolytics: what exists and what is coming?
In recent years, the field has changed completely. In the United States, two drugs have already been approved for MASH with stage F2 to F3 fibrosis. The first is resmetirom, a pill that acts on the thyroid hormone receptor in the liver. In its phase 3 trial, fibrosis improved in about a quarter of patients after one year, compared with 14.2% on placebo. The second is semaglutide, the active ingredient in Wegovy, which was approved following another phase 3 trial.
In addition, several drugs are in advanced development. Tirzepatide, the active ingredient in Mounjaro, resolved inflammation in 44% to 62% of patients in a phase 2 trial, compared with 10% on placebo. Survodutide and retatrutide are also being tested in fatty liver. Alongside them, drugs from other families are advancing. One is lanifibranor, whose phase 3 results are expected in the coming months. Another is efruxifermin, which mimics a hormone called FGF21.
Most of these drugs work through metabolism: they reduce fat, weight and the burden on the liver. The senolytic approach, by contrast, targets a completely different mechanism, the senescent cells themselves. A third direction focuses on the crosstalk between scar-forming cells and inflammatory cells, as I described in my article on a new mechanism in liver fibrosis.
We cannot compare the numbers directly, because the trials differ in size and duration. The resmetirom trial, for instance, included 966 patients, while the senolytic trial included 31. An open question for the future is whether combining the two approaches would work better. The current study did not test this.
What do senolytics for fatty liver mean for patients today?
The most important message: senolytics for fatty liver are not yet an available treatment. Do not take dasatinib on your own. It is a cancer drug with real side effects, and it requires a prescription and medical monitoring. Likewise, a quercetin supplement alone is not what was tested here. The trial tested the combination, at a set dose and schedule, under close supervision.
On the other hand, we already have tools that work. Weight loss reduces liver fat, and it often improves inflammation and early scarring as well. That is why a healthy diet, physical activity and good diabetes control are the foundation. When appropriate, we can add medical treatment for obesity or bariatric surgery.
Finally, it is worth knowing the state of your liver. If you have fatty liver, ask your doctor about assessing your fibrosis stage. Simple blood tests and a liver stiffness scan can do this, without a biopsy. Early diagnosis allows treatment before irreversible damage occurs.
Questions and answers about senolytics for fatty liver
Can I get senolytic treatment for fatty liver today?
No. The treatment is at an early research stage and is not approved for fatty liver in any country. Large, long trials must first confirm its efficacy and safety.
Can a quercetin supplement help the liver?
This study did not test quercetin on its own, so we cannot draw conclusions about the supplement. The researchers chose the combination because the two compounds hit complementary survival mechanisms.
Why is the treatment given for only a few days in each cycle?
Senescent cells do not divide, and they build up again slowly. So a short “hit” every few weeks is enough. This also limits exposure to the drug and its side effects.
Could clearing senescent cells cause harm?
That is an open question. Cellular senescence protects against cancer and helps wounds heal. In this trial, the researchers saw no change in cancer-related pathways, but follow-up was short. Only long-term studies can answer this.
The bottom line on senolytics for fatty liver
For the first time, a controlled trial shows that clearing senescent cells may reverse scarring in the human liver. This is a new idea that bridges the science of aging and metabolic medicine. Still, the trial was small and short, and its result awaits confirmation in larger trials. Until then, the proven way to protect your liver is a healthy lifestyle, weight loss and personalized medical care. I discuss this approach further in my article what really slows aging.
This article provides general information only and is not a substitute for personalized medical advice.
References
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Hallmarks of aging: an expanding universe
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Cellular senescence and senolytics: the path to the clinic
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
Fisetin is a senotherapeutic that extends health and lifespan
Senolytic CAR T cells reverse senescence-associated pathologies
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Disclosure, per the paper: the Dutch public research funder ZonMw funded the trial, and the funders had no role in its design or data analysis. Two of the authors have a financial interest in patents on senolytic drugs owned by the Mayo Clinic.
